Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,741 | $1,907 | $1,629 | $1,860 |
| % Growth | -8.7% | 17.1% | -12.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,741 | $1,907 | $1,629 | $1,860 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $25,838 | $27,430 | $29,136 | $33,609 |
| G&A Expenses | $10,638 | $11,445 | $13,773 | $15,262 |
| SG&A Expenses | $10,638 | $11,445 | $13,773 | $15,262 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $14,737 |
| Operating Expenses | $36,476 | $38,875 | $42,909 | $63,608 |
| Operating Income | -$34,735 | -$36,968 | -$41,280 | -$61,748 |
| % Margin | -1,995.1% | -1,938.5% | -2,534.1% | -3,319.8% |
| Other Income/Exp. Net | $2,485 | $2,898 | $3,659 | $9,595 |
| Pre-Tax Income | -$32,250 | -$34,070 | -$37,621 | -$52,153 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32,250 | -$34,070 | -$37,621 | -$52,153 |
| % Margin | -1,852.4% | -1,786.6% | -2,309.5% | -2,803.9% |
| EPS | -0.27 | -0.29 | -0.32 | -0.44 |
| % Growth | 6.9% | 9.4% | 27.3% | – |
| EPS Diluted | -0.27 | -0.29 | -0.32 | -0.44 |
| Weighted Avg Shares Out | 118,999 | 118,528 | 118,376 | 117,794 |
| Weighted Avg Shares Out Dil | 118,999 | 118,528 | 118,376 | 117,794 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,575 | $2,921 | $3,336 | $3,874 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,227 | $3,278 | $3,333 | $4,813 |
| EBITDA | -$29,023 | -$30,792 | -$37,947 | -$42,198 |
| % Margin | -1,667% | -1,614.7% | -2,329.5% | -2,268.7% |